CY1124366T1 - Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιας - Google Patents

Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιας

Info

Publication number
CY1124366T1
CY1124366T1 CY20211100509T CY211100509T CY1124366T1 CY 1124366 T1 CY1124366 T1 CY 1124366T1 CY 20211100509 T CY20211100509 T CY 20211100509T CY 211100509 T CY211100509 T CY 211100509T CY 1124366 T1 CY1124366 T1 CY 1124366T1
Authority
CY
Cyprus
Prior art keywords
sleep
subject
increasing
methods
reduction
Prior art date
Application number
CY20211100509T
Other languages
Greek (el)
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics, Inc. filed Critical Ovid Therapeutics, Inc.
Publication of CY1124366T1 publication Critical patent/CY1124366T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
CY20211100509T 2014-06-06 2021-06-10 Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιας CY1124366T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Publications (1)

Publication Number Publication Date
CY1124366T1 true CY1124366T1 (el) 2022-07-22

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20211100509T CY1124366T1 (el) 2014-06-06 2021-06-10 Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιας
CY20211100510T CY1124368T1 (el) 2014-06-06 2021-06-10 Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100510T CY1124368T1 (el) 2014-06-06 2021-06-10 Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman

Country Status (20)

Country Link
US (11) US20150352085A1 (enExample)
EP (3) EP3795156A1 (enExample)
JP (4) JP2017516868A (enExample)
AR (1) AR100772A1 (enExample)
AU (4) AU2015269667B2 (enExample)
CA (1) CA2950845C (enExample)
CY (2) CY1124366T1 (enExample)
DK (2) DK3151832T3 (enExample)
ES (2) ES2875742T3 (enExample)
HR (2) HRP20210901T1 (enExample)
HU (2) HUE055400T2 (enExample)
IL (2) IL249287B (enExample)
LT (2) LT3151832T (enExample)
MX (2) MX391502B (enExample)
PL (2) PL3151832T3 (enExample)
PT (2) PT3151832T (enExample)
RS (2) RS62007B1 (enExample)
SI (2) SI3151832T1 (enExample)
SM (2) SMT202100343T1 (enExample)
WO (1) WO2015187851A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3065782B8 (en) 2013-11-05 2021-05-26 Elena Molokanova Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels
EP3795156A1 (en) 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
US10080898B2 (en) 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
EP3833351A4 (en) * 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
KR20210110585A (ko) * 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
JP2022524927A (ja) 2019-02-02 2022-05-11 ステモニックス インコーポレイティド 創薬のためのヒトスフェロイドの使用方法
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
EP3982937A4 (en) * 2019-07-15 2022-08-10 Ovid Therapeutics Inc. PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤
AU2024220869A1 (en) 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
JP5909750B2 (ja) 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン
CN102137667A (zh) * 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物
EP3795156A1 (en) * 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
US20160038469A1 (en) 2016-02-11
JP2021178836A (ja) 2021-11-18
EP3151832A1 (en) 2017-04-12
IL249287B (en) 2021-03-25
MX2020012404A (es) 2022-04-11
US20170071917A1 (en) 2017-03-16
LT3372229T (lt) 2021-07-12
AR100772A1 (es) 2016-11-02
JP2020063264A (ja) 2020-04-23
PT3372229T (pt) 2021-06-17
US20180015076A1 (en) 2018-01-18
DK3372229T3 (da) 2021-06-14
US20250025448A1 (en) 2025-01-23
SI3151832T1 (sl) 2021-08-31
MX380868B (es) 2025-03-12
AU2020217342B2 (en) 2021-10-07
IL268960B (en) 2021-05-31
US11278529B2 (en) 2022-03-22
US9339495B2 (en) 2016-05-17
IL249287A0 (en) 2017-02-28
IL268960A (en) 2019-10-31
HRP20210901T1 (hr) 2021-09-17
CY1124368T1 (el) 2022-07-22
WO2015187851A1 (en) 2015-12-10
US9744159B2 (en) 2017-08-29
SMT202100343T1 (it) 2021-07-12
EP3372229B1 (en) 2021-03-24
US20170087133A1 (en) 2017-03-30
HRP20210902T1 (hr) 2021-09-17
ES2875742T3 (es) 2021-11-11
US20230051859A1 (en) 2023-02-16
AU2020217342A1 (en) 2020-08-27
CA2950845C (en) 2023-04-25
PT3151832T (pt) 2021-06-15
CA2950845A1 (en) 2015-12-10
LT3151832T (lt) 2021-07-12
MX2016016136A (es) 2017-07-05
ES2876350T3 (es) 2021-11-12
AU2015269667A1 (en) 2016-12-22
AU2024202604A1 (en) 2024-05-09
HUE055155T2 (hu) 2021-11-29
US20220016091A1 (en) 2022-01-20
EP3151832B1 (en) 2021-03-24
US9801864B2 (en) 2017-10-31
US20180303805A1 (en) 2018-10-25
JP2023123442A (ja) 2023-09-05
RS62007B1 (sr) 2021-07-30
PL3372229T3 (pl) 2021-10-04
SMT202100340T1 (it) 2021-07-12
AU2015269667B2 (en) 2020-07-30
JP2017516868A (ja) 2017-06-22
SI3372229T1 (sl) 2021-09-30
US20160228418A1 (en) 2016-08-11
RS62006B1 (sr) 2021-07-30
PL3151832T3 (pl) 2021-10-25
EP3795156A1 (en) 2021-03-24
HUE055400T2 (hu) 2021-11-29
AU2022200085A1 (en) 2022-02-03
DK3151832T3 (da) 2021-06-14
US9446028B2 (en) 2016-09-20
US20170273956A1 (en) 2017-09-28
MX391502B (es) 2025-03-21
EP3151832A4 (en) 2018-01-17
US20150352085A1 (en) 2015-12-10
EP3372229A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
MX380868B (es) Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
CY1123914T1 (el) Αντιμετωπιση των αυξημενων επιπεδων ηωσινοφιλων και/ή βασεοφιλων
CY1122624T1 (el) Θεραπεια συνδυασμου του καρκινου
CY1125621T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση των διαταραχων ανωμαλης, ακουσιας κινησης
CY1125089T1 (el) Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
CY1121228T1 (el) 19-νορ c3,3-διϋποκατεστημενα c21-n-πypazoλyλ στεροειδη και μεθοδοι χρησης αυτων
MX2024010140A (es) Nuevos metodos.
CY1122671T1 (el) Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
MX388781B (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c.
EA201590693A1 (ru) Ингибиторы gdf-8
CL2018000119A1 (es) Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret.
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
CY1124078T1 (el) Συνθεσεις που περιλαμβανουν αναστολεα λυσινης ειδικης απομεθυλασης-1 που εχει δακτυλιο πυριμιδινης και χρηση αυτων στη θεραπεια καρκινου
CY1121855T1 (el) Παραγωγα βενζιμιδαζολιου ως αναστολεις βρωμοπεδιου
CY1119939T1 (el) Παραγωγα 2,3-διϋδρο-βενζο[1,4]οξαζιν και σχετικες ενωσεις οπως αναστολεις φωσφοϊνοσιτινης-3 κινασης (ρι3κ) για τη θεραπεια παραδειγματος χαρην της ρευματοειδους αρθριτιδας
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
JOP20190076B1 (ar) مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
UY36308A (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
CY1120026T1 (el) Κρενολανιμπη για την θεραπεια μεταλλαγμενων me flt3 πολλαπλασιαστικων διαταραχων
CY1119642T1 (el) Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου
EA201792116A1 (ru) Ингибитор янус-киназы
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων